Key result
Cardiac troponins with early markers enable rapid, accurate diagnosis of acute myocardial infarction.
Why the study?
The diagnostic accuracy and timing of various cardiac biomarkers for acute myocardial infarction in patients with chest pain require clarification to optimize early diagnosis.
How do different cardiac biomarkers compare in the early and specific diagnosis of acute myocardial infarction in patients with chest pain?
How do different cardiac biomarkers compare in the early and specific diagnosis of acute myocardial infarction in patients with chest pain?
A combination of rapid markers (myoglobin, CK-MB) and highly specific markers (troponins) is recommended for the optimal diagnosis of acute myocardial infarction in patients presenting with chest pain.
Supports combined biomarker strategies for AMI diagnosis; leaves open prospective validation with high-sensitivity assays.
The enzyme activities of creatine kinase (CK), its isoenzyme MB (CK-MB) and of lactate dehydrogenase isoenzyme 1 (LD-1) have been used for years in diagnosing patients with chest pain in order to differentiate patients with acute myocardial infarction (AMI) from non-AMI patients. These methods are easy to perform as automated analyses, but they are not specific for cardiac muscle damage. During the early 90's the situation changed. First, creatine kinase ME mass (CK-MB mass) replaced the measurement of CK-MB activity. Subsequently cardiac-specific proteins, troponin T (cTnT) and troponin I (cTnI) appeared and displacing LD-1 analysis. However, troponin concentrations in blood increase only from four to six hours after onset of chest pain. Therefore a rapid marker such as myoglobin, fatty acid binding protein or glycogen phosphorylase BB could be used in early diagnosis of AMI. On the other hand, CK-MB isoforms alone may also be useful in rapid diagnosis of cardiac muscle damage. Myoglobin, CK-MB mass, cTnT and cTnI are nowadays widely used in diagnosing patients with acute chest pain. Myoglobin is not cardiac-specific and therefore requires supplementation with some other analyses such as troponins to support the myoglobin value. Troponins are very highly cardiac-specific. Only the sera of some patients with severe renal failure, which requires hemodialysis, have elevated cTnT and/or cTnI without there being any evidence of cardiac damage. The latest studies have shown that elevated troponin levels in sera of hemodialysis patients point to an increased risk of future cardiac events in a similar manner to the elevated troponin values in sera of patients with unstable angina pectoris. In addition, the bedside tests for cTnT and cTnI alone- or together with myoglobin and CK-ME mass can be used instead of quantitative analyses in the diagnosis of patients with chest pain. These rapid tests are easy to perform and they do not require expensive instrumentation. For the diagnosis of patient with chest pain, routinely myoglobin and CK-ME mass measurements should be performed whenever they are requested (24 h/day) and cTnT or cTnI on admission to the hospital and then 4-6 and 12 hours later and maintained less than 10% in imprecision.
No takes yet. Share an insight, caveat, or question.
Kyung Dong Kim (2001) conducted a review in Acute Coronary Syndrome. Cardiac biomarkers (troponins, myoglobin, CK-MB) was evaluated. Cardiac-specific troponins, alongside rapid markers like myoglobin and CK-MB mass, are essential for the early and accurate diagnosis of acute myocardial infarction in patients with chest pain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: